Gianfranco Bittar-Carlini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gianfranco Bittar-Carlini has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Badri Aryal
Department of Internal Medicine, John H Stroger, Jr. Hospital of Cook County, Chicago, IL, USA
1 shared publication - Bhanu Siva Mohan Pinnam
Department of Internal Medicine, John H. Stroger, Jr Hospital of Cook County, Chicago, IL, USA
1 shared publication - Dae Yong Park
Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA
1 shared publication - Diana De Oliveira-Gomes
Department of Research, Foundation for Clinic, Public Health, and Epidemiological Research of Venezuela (FISPEVEN), Caracas, VEN
1 shared publication - Hisham F. Bahmad
Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA
1 shared publication - Manoj Kumar
John H. Stroger Jr. Hospital of Cook County, Chicago, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by XMLink in International Journal of Heart Failure
- Vol. 7 (1) , 21-29
Predictors and Trends of 30-day Readmissions in Patients With Acute Decompensated Heart Failure With Preserved Ejection Fraction: Insight From the National Readmission Database
DeAngelo S, et al. Int J Heart Fail. 2025 Jan;7(1):21-29. https://doi.org/10.36628/ijhf.2024.0041
- 1 January 2025
- Published by XMLink in International Journal of Heart Failure
- Vol. 7 (1) , 21-29
Open AccessPredictors and Trends of 30-day Readmissions in Patients With Acute Decompensated Heart Failure With Preserved Ejection Fraction: Insight From the National Readmission Database
DeAngelo S, et al. Int J Heart Fail. 2025 Jan;7(1):21-29. https://doi.org/10.36628/ijhf.2024.0041
- 2 May 2024
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 37 (4) , 560-568
Seasonal variations in admissions for atrial fibrillation or atrial flutter in the Northeast and the Midwest regions of the United States
Previous studies conflict on whether seasonal variability exists in atrial fibrillation (AF) admissions, and contemporary studies are lacking. We identified admissions for AF or atrial flutter in the Midwest and Northeast regions of the US from the National Inpatient Database for 2016 to 2020, grouped them into the four seasons (spring, summer, fall, winter), and compared the number of admissions. Subgroup analyses were performed stratified to sex, age, race, AF alone, and geographical regions. A total of 955,320 admissions for AF or atrial flutter occurred. The number of admissions was highest during winter (243,990, 25.5% of the total), followed by fall (239,250, 25.0% of the total), summer (236,910, 24.8% of the total), and spring (235,170, 24.6% of the total). The differences were statistically significant (P < 0.001). An increasing trend in the number of admissions was observed from March to February of the next year (P trend <0.001). Admissions were most common in the winter and least common in the spring in subgroups of both sexes, age ≥65 years, Whites, non-Whites, AF alone, Northeast region, and Midwest region. Contemporary analysis of a national database demonstrates seasonal variability in the number of admissions for AF, with a slight increase observed during the winter.
- 2 May 2024
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 37 (4) , 560-568
Seasonal variations in admissions for atrial fibrillation or atrial flutter in the Northeast and the Midwest regions of the United States
Previous studies conflict on whether seasonal variability exists in atrial fibrillation (AF) admissions, and contemporary studies are lacking. We identified admissions for AF or atrial flutter in the Midwest and Northeast regions of the US from the National Inpatient Database for 2016 to 2020, grouped them into the four seasons (spring, summer, fall, winter), and compared the number of admissions. Subgroup analyses were performed stratified to sex, age, race, AF alone, and geographical regions. A total of 955,320 admissions for AF or atrial flutter occurred. The number of admissions was highest during winter (243,990, 25.5% of the total), followed by fall (239,250, 25.0% of the total), summer (236,910, 24.8% of the total), and spring (235,170, 24.6% of the total). The differences were statistically significant (P < 0.001). An increasing trend in the number of admissions was observed from March to February of the next year (P trend <0.001). Admissions were most common in the winter and least common in the spring in subgroups of both sexes, age ≥65 years, Whites, non-Whites, AF alone, Northeast region, and Midwest region. Contemporary analysis of a national database demonstrates seasonal variability in the number of admissions for AF, with a slight increase observed during the winter.
- Open Access
Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing
Colorectal cancer (CRC) is the third most common cancer in the world. Despite improvement in standardized screening methods and the development of promising therapies, the 5-year survival rates are as low as 10% in the metastatic setting. The increasing life expectancy of the general population, higher rates of obesity, poor diet, and comorbidities contribute to the increasing trends in incidence. Drug repurposing offers an affordable solution to achieve new indications for previously approved drugs that could play a protagonist or adjuvant role in the treatment of CRC with the advantage of treating underlying comorbidities and decreasing chemotherapy toxicity. This review elaborates on the current data that supports drug repurposing as a feasible option for patients with CRC with a focus on the evidence and mechanism of action promising repurposed candidates that are widely used, including but not limited to anti-malarial, anti-helminthic, anti-inflammatory, anti-hypertensive, anti-hyperlipidemic, and anti-diabetic agents.
Open AccessOvercoming Therapy Resistance in Colon Cancer by Drug Repurposing
Colorectal cancer (CRC) is the third most common cancer in the world. Despite improvement in standardized screening methods and the development of promising therapies, the 5-year survival rates are as low as 10% in the metastatic setting. The increasing life expectancy of the general population, higher rates of obesity, poor diet, and comorbidities contribute to the increasing trends in incidence. Drug repurposing offers an affordable solution to achieve new indications for previously approved drugs that could play a protagonist or adjuvant role in the treatment of CRC with the advantage of treating underlying comorbidities and decreasing chemotherapy toxicity. This review elaborates on the current data that supports drug repurposing as a feasible option for patients with CRC with a focus on the evidence and mechanism of action promising repurposed candidates that are widely used, including but not limited to anti-malarial, anti-helminthic, anti-inflammatory, anti-hypertensive, anti-hyperlipidemic, and anti-diabetic agents.